BRPI0415562B8 - método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio - Google Patents
método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaioInfo
- Publication number
- BRPI0415562B8 BRPI0415562B8 BRPI0415562A BRPI0415562A BRPI0415562B8 BR PI0415562 B8 BRPI0415562 B8 BR PI0415562B8 BR PI0415562 A BRPI0415562 A BR PI0415562A BR PI0415562 A BRPI0415562 A BR PI0415562A BR PI0415562 B8 BRPI0415562 B8 BR PI0415562B8
- Authority
- BR
- Brazil
- Prior art keywords
- carcinoma
- lap
- prognostic
- immunoassay kit
- patient
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma. a presente invenção proporciona um reagente para avaliação prognóstica de pacientes com carcinoma, compreendendo um anticorpo anti-p-lap como um ingrediente ativo. também, a presente invenção proporciona um método para a determinação de p-lap que é um fator prognóstico em pacientes com carcinoma compreendendo (a) uma etapa de contatar tecidos de carcinoma obtidos de pacientes com carcinoma por operação cirúrgica com um anticorpo anti-p-lap e (b) uma etapa de medir a intensidade da reação específica de antígeno-anticorpo entre p-lap presente nos tecidos de carcinoma e o anticorpo anti-p-lap.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003360638 | 2003-10-21 | ||
PCT/JP2004/013883 WO2005038462A1 (en) | 2003-10-21 | 2004-09-15 | Method for prognostic evaluation of carcinoma using anti-p-lap antibody |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0415562A BRPI0415562A (pt) | 2007-01-02 |
BRPI0415562B1 BRPI0415562B1 (pt) | 2020-02-04 |
BRPI0415562B8 true BRPI0415562B8 (pt) | 2021-07-27 |
Family
ID=34463417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0415562A BRPI0415562B8 (pt) | 2003-10-21 | 2004-09-15 | método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio |
Country Status (5)
Country | Link |
---|---|
US (1) | US7666605B2 (pt) |
JP (1) | JP4635004B2 (pt) |
BR (1) | BRPI0415562B8 (pt) |
CA (1) | CA2542823C (pt) |
WO (1) | WO2005038462A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1984546A4 (en) * | 2006-01-24 | 2009-09-23 | Univ British Columbia | POLYMORPHISMS OF THE VASOPRESSIN SIGNALING PATH AS INDICATORS OF THE EVOLUTION OF STATUS OF SUBJECTS IN SUBJECTS SERIOUSLY REACHED |
US7689554B2 (en) * | 2006-02-28 | 2010-03-30 | Yahoo! Inc. | System and method for identifying related queries for languages with multiple writing systems |
FR2933411B1 (fr) | 2008-07-04 | 2013-04-19 | Univ Joseph Fourier | Utilisation de la proteine irap pour la mise en oeuvre de methodes de diagnostic et de pronostique |
FR2945808B1 (fr) * | 2009-05-20 | 2013-12-27 | Univ Joseph Fourier | Peptides marques et leur utilisation pour le dosage d'irap circulant |
JP7313005B2 (ja) * | 2019-06-25 | 2023-07-24 | 医療法人三栄会 | がんのバイオマーカーおよびがんの発症を判定する方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4129704B2 (ja) * | 1998-09-22 | 2008-08-06 | ニプロ株式会社 | ロイシンアミノペプチダーゼ活性測定用試薬 |
-
2004
- 2004-09-15 US US10/575,763 patent/US7666605B2/en active Active
- 2004-09-15 CA CA2542823A patent/CA2542823C/en active Active
- 2004-09-15 WO PCT/JP2004/013883 patent/WO2005038462A1/en active Application Filing
- 2004-09-15 JP JP2006516530A patent/JP4635004B2/ja active Active
- 2004-09-15 BR BRPI0415562A patent/BRPI0415562B8/pt active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2542823C (en) | 2015-05-26 |
US7666605B2 (en) | 2010-02-23 |
JP4635004B2 (ja) | 2011-02-16 |
JP2007509313A (ja) | 2007-04-12 |
BRPI0415562B1 (pt) | 2020-02-04 |
BRPI0415562A (pt) | 2007-01-02 |
WO2005038462A1 (en) | 2005-04-28 |
CA2542823A1 (en) | 2005-04-28 |
US20070020705A1 (en) | 2007-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120296T1 (el) | ΔΙΑΛΥΤΟΣ ΥΠΟΔΟΧΕΑΣ ΕΝΕΡΓΟΠΟΙΗΤΗ ΤΟΥ ΠΛΑΣΜΙΝΟΓΟΝΟΥ ΤΥΠΟΥ ΟΥΡΟΚΙΝΑΣΗΣ (suPAR) ΩΣ ΔΙΑΓΝΩΣΤΙΚΟΣ ΔΕΙΚΤΗΣ ΓΙΑ ΧΑΜΗΛΟΥ ΒΑΘΜΟΥ ΦΛΕΓΜΟΝΗ | |
BRPI0516674A (pt) | método de análise de mal de alzheimer e reagente de diagnóstico | |
DK1889059T3 (da) | Fremgangsmåde til forbedret immunoassay | |
DE602005015894D1 (de) | Diagnostische testvorrichtung | |
BRPI0414030A (pt) | método para detectar desordens neoplásicas em uma amostra corporal solubilizada | |
BR112017021305A2 (pt) | dispositivo de teste de fluxo lateral, e, método e kit para detecção quantitativa de um analito em uma amostra de saliva | |
EP2319941A3 (en) | Method and apparatus for correlating levels of biomarker products with disease | |
WO2007002579A3 (en) | Assay cartridges and methods for point of care instruments | |
ATE423217T1 (de) | Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten | |
HK1115636A1 (en) | Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1 | |
BR112013000869A2 (pt) | método para diagnóstico de câncer de próstata (pca) com uma sensibilidade desejada em um sujeito; método para monitorar a progressão do câncer de próstata (pca) em um sujeito; método para avaliar se um sujeito tem que ser submetido a uma biópsia de próstata; kit compreendendo um primeiro componente e, opcionalmente, um segundo componente e uso de um kit | |
SG171691A1 (en) | Biomarkers for diagnosing multiple sclerosis, and methods thereof | |
BRPI0509978A (pt) | uso de padrão proteÈmico de plasma para diagnóstico, classificação, previsão de resposta à terapia e comportamento clìnico, estratificação de terapia, e monitoramento de doença em malignidades hematológicas | |
EP1836956A3 (en) | Activity-induced energy expenditure estimating instrument | |
WO2008132464A3 (en) | Mek5 and related proteins as biomarkers of neurodegenerative diseases | |
ATE534905T1 (de) | Cop1-moleküle und verwendungen davon | |
BR0317394A (pt) | Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal | |
Faix et al. | Progress in standardizing and harmonizing thyroid function tests | |
BRPI0512948A (pt) | biomarcadores de mal de alzheimer | |
DE602005013430D1 (de) | Verwendung von asc als marker für kolorektalkarzinome | |
ATE406579T1 (de) | Verfahren zur diagnose von tumoren | |
HK1136873A1 (en) | Use of nnmt as a marker for lung cancer | |
BRPI0415562B8 (pt) | método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio | |
ATE369564T1 (de) | Differenzielles immunoassay für myoglobin | |
DE602005010548D1 (de) | Verbessertes verfahren zur diagnose des akuten koronarsyndroms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: SUNTORY HOLDINGS LIMITED (JP) Free format text: TRANSFERIDO DE: SUNTORY LIMITED |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |